Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amivantamab (Primary) ; Lazertinib (Primary) ; Osimertinib
  • Indications Brain metastases; Liver metastases; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MARIPOSA
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 30 Aug 2024 According to Onco360 media release, company has been selected as a pharmacy partner by Johnson & Johnson for LAZCLUZE (lazertinib) approved for the first-line treatment, in combination with RYBREVANT (amivantamab-vmjw) as a chemotherapy-free regimen, of adult patients with metastatic non-small cell lung cancer (NSCLC)
    • 27 Aug 2024 According to Johnson & Johnson media release, data from this trial to be featured at the 2024 World Conference on Lung Cancer (WCLC), (Sept 7-10) in San Diego, CA and the European Society for Medical Oncology (ESMO) 2024 Congress, (Sept 13-17) in Barcelona, Spain.
    • 20 Aug 2024 According to a Johnson & Johnson media release, results from this study were published in The New England Journal of Medicine and in Annals of Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top